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Sum m ary. Recent studies describe families with both 
elevated plasma HRG levels and thrombosis. In order to 
study the possibility that allelic variants of the HRG locus are 
associated with differences in HRG level, we studied linkage 
between HRG levels and a dinucleotide repeat polymorphism 
in a Dutch family which was selected on the presence of both 
thrombosis and elevated plasma HRG levels. No other 
known risk factors from thrombosis were found in this 
family. Linkage was calculated between the dinucleotide 
repeat and the HRG level considering the HRG level as a 
quantitative phenotype assuming a population prevalence of 
elevated HRG of 5%. Two classes of HRG levels were defined 
by a mean and a variance: one class with normal HRG levels 
and a second class with high HRG levels. Using a mean HRG 
level of 99% for individuals with a normal HRG level and 
145% for individuals with high HRG, a maximum lod score 
of 4-17 (odds in favour of linkage of 22 000 :1 ) was found at
a recombination fraction of 0, indicating linkage. Consider­
ing the pedigree, an association was found between the 
presence of a specific allele (no. 6) of the dinucleotide repeat 
polymorphism and plasma HRG levels. Family members 
carrying allele 6 were found to have higher HRG plasma 
levels compared with family members lacking allele 6 (149% 
v 109% respectively). We conclude that in this family, 
linkage is found between the HRG locus and the HRG level, 
and that a HRG gene coupled to allele 6 of the dinucleotide 
polymorphism is associated with elevated plasma HRG 
levels. No evidence was found for a causal relationship 
between elevated plasma HRG levels and thrombosis in this 
family.
Keywords: family, linkage, histidine-rich glycoprotein, HRG, 
thrombosis, polymorphism.
Histidine-rich glycoprotein (HRG) is a single-chain glyco­
protein which is found in human plasma at a concentration 
of 100 /ig/ml (Heimburger et a l  1972). A pool of HRG is also 
stored in the a-granules of platelets at a concentration of 
about O-4/xg/lO9 platelets (Leung et al, 1983; Hoffmann 
et al, 1993). Plasma HRG is produced by the parenchymal 
cells of the liver (Hennis et al, 1991) and the source of 
platelet HRG is probably the megakaryocyte (Leung et al, 
1983). Up to now, the exact physiological function of HRG is 
unknown, but it has been proposed that HRG can act as a 
modulator of coagulation and fibrinolysis (Koide, 1988). 
HRG has been shown to interact with a variety of 
haemostatic factors such as heparin (Koide et al, 1982),
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fibrinogen (Leung, 1986) and plasminogen (Lijnen et al, 
1980). The ability of HRG to bind plasminogen is thought to 
affect fibrinolysis by reducing the amount of fibrin-bound 
plasminogen which is available for activation into plasmin. 
An elevation of the HRG level in plasma may therefore 
reduce the fibrinolytic potency.
Supporting evidence for this hypothesis is presented in 
several studies of patients with thrombosis (Samama et al, 
1983; Engesser et al, 1988; Ehrenforth et al, 1994). In these 
patients a higher prevalence of elevated HRG levels has been 
observed. Moreover, in recent years six families have 
been described in which both thromboembolic disease and 
elevation of plasma HRG was observed (Falkon et al, 1992; 
Angles-Cano et al, 1993; Castaman et al, 1993; Hoffmann 
et al, 1993; Engesser et al, 1987). All members of these 
families with a history of thrombosis had elevated levels of
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Fig 1. Pedigree of family. Filled symbols indicate elevated HRG plasma levels (^  145%); dashed symbols indicate a history of thrombosis. Family members who were not available for investigation 
are indicated with N.A. The HRG level and the genotype with respect to the dinucleotide repeat are shown below each individual. The proband is indicated by an arrow.
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HRG, although a few family members had elevated HRG 
levels and no history of thrombosis. However, up to now 
it is unknown whether the relationship between congeni­
tally elevated HRG levels and thrombosis is causal or
coincidental.
Recently, a twin study was presented in which genetic 
factors were found to explain 69% of the variance in plasma 
HRG levels (Boomsma et al, 1993). From this study it is clear 
that a familial elevation of HRG levels cannot be attributed 
to common environmental influences shared by family 
members, but has to be attributed to genetic influences 
shared by parents and children. Several genes, among them 
the HRG gene which is localized on chromosome 3q28-q29
France) with sodium citrate as anticoagulant. Samples 
were kept on ice and centrifuged immediately at 30000  
for 30min at 4 tJC. Plasma was separated and stored at 
—80°C until use. The remaining blood cells and buffy coat of 
the samples were used for isolation of genomic DNA.
Coagulation assays. Assays of activated partial thrombo­
plastin time, prothrombin time, thrombin clotting time, 
fibrinogen (Clauss method) and factor VIII coagulant activity
were according to
Coagulant activities of factor V and VII were measured by 
one-stage clotting assays, using factor V and VII deficient 
plasma and rabbit brain thromboplastin (Simplastin-plus, 
General Diagnostics, Morris Plains, U.S.A.). Protein S
(Hennis et al, may be responsible for this genetic
influence. In some reports it has been speculated that the 
inherited elevated HRG levels find their cause in an abnormal 
HRG gene (Hoffmann et al, 1993; Schved et al, 1.991), but up 
to now no association has been reported 
HRG levels and a specific allele of the HRG gene.
To investigate the role of the HRG locus in congenital 
elevation of HRG, we studied the inheritance pattern of a 
multi-allelic dinucleotide repeat polymorphism within the 
HRG gene (Hennis et al, 1994) in a Dutch family with both 
elevated HRG levels and thrombosis. Quantitative linkage 
analysis suggested involvement of the HRG locus. One allele 
of the highly informative dinucleotide repeat was found to be 
linked with high plasma HRG levels.
antigen was measured by a radioimmunoassay previously 
described by Bertina et al (1985). Antithrombin III activity 
was determined by a spectrophotometric assay (Coatest, 
Kabivitrum, Sweden). Von Willebrand factor antigen, factor 
II and factor X antigen, heparin cofactor antigen (Bertina 
et al, 1987) and protein C antigen (Bertina et al, 1982) were 
measured by Laurell rocket electroimmunoassay, 
anticoagulant response to activated protein C (APC) was 
measured using Coatest® APC resistance (Chromogenix, 
Sweden). Protein C activity was determined using a new 
assay based on the measurement of coagulation times on a
Coag-A-Mate RA-4 (Organon Teknika, The Netherlands). 
The assay has been developed by Organon Teknika and will 
be available in the near future. The procedure was started 
by the reconstitution of a vial of Protac (Pentapharm,
METHODS
Case report and family history. The proband with 
thromboembolic disease and elevated HRG came to our 
attention in a previous study (Engesser et al, 1988). The 
proband (II-.18, see pedigree in Fig 1) was a 46-year-old man
seen for of recurrent thromboembolism;
the age of 75. One of the proband's sisters
venous thrombosis (DVT) in the right leg and pulmonary 
embolism after groin rupture surgery at the age of 32; 1 year 
later DVT in the left leg after stopping oral anticoagulant 
therapy with coumarln. At the age of 35 a spontaneous 
thrombosis was diagnosed in the right leg. In all three 
episodes DVT was confirmed by phlebography.
The pedigree is shown in Fig 1. Persons with a history of 
thrombosis are indicated. Both parents of the patient suffered 
from DVT. The father (I-1) had DVT in the right leg at the 
of 77. The mother (1-2) had DVT in the right leg at
•1) had
recurrent DVT after an operation at the age of 40. A brother 
of the proband (II-3) had DVT in the right leg at the age of 29 
after a trauma. One family member (II-14) who is related by 
marriage had postoperative DVT in a leg. Another family 
member (11-12) who is related by marriage was treated with 
percutane transluminal coronary angiography (PTCA).
Oral contraceptives were used by four females in 
generation III (11, 15, 17 and 18).
Blood collection. This study was approved by the Medical 
Ethical Committee of HGO-TNO and informed consent was 
obtained from patients and controls.
Blood was collected from family members by a single 
venipuncture into vacutalner tubes (Becton Dickinson,
Switzerland) in 6 ml APTT-L (Platelin-L , Organon Teknika) 
reagent (Protac concentration: 0-5U/ml). The APTT/Protac 
solution was allowed to stand for 15min at 0°C. A 
calibration curve was made by
0, 5 and 10
s was
;s in Protein C 
10 times in 
100 /il of the
Plasma (Organon 
depleted plasma. Plasma of
C
calibration solutions or the diluted f 
into the RA-4 and the measurement was started. After a 
fixed heating time, which cannot be influenced, 125 /d 
of APTT/Protac solution was added via the Coag-A-Mate 
RA-4. Following an incubation time of 220 s at 37°C, 100 /d
CaCl2 solution (Platelin , Organon Teknika) was added and 
coagulation times were registered. Protein S activity was
with essentially
however S deficient plasma, 12 5 /A
100 ul of APTT/Protac.
assays. Plasminogen (Pig) 
determined on a MLA 1000C (Medical Laboratory Automa­
tion, Pleasantville, New York, U.S.A.) using a chromogcnlc
, Baxter, Miami, U.S.A.). For calibration Dade 
N (Lot no. 540.046, Baxter, U.S.A.) was used. The 
assigned value of the plasminogen level in this plasma is 
106%. a 2-antiplasmin activity was measured by a chromo- 
genic assay according to Friberger et al (1978). Tissue-type 
plasminogen activator (t-PA) activity was measured accord­
ing to Verheijen et al (1982). Urokinase-type plasminogen 
activator (u-PA) antigen and activity were determined using 
an ELISA (Blnnema et a l  1986) and a biological immuno­
assay (van Hinsbergh et al, 1 
activity of the intrinsic plasminogen activating system was
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determined on fibrin plates, using euglobulin fractions from 
plasma, prepared in the presence of dextran sulphate, with 
or without the addition of antibodies against u-PA (Kluft 
et al, 1984). Plasminogen activator inhibitor (PAI) activity 
was measured according to Verheijen et al (1984).
Assay of histidine-rich glycoprotein. Measurement of plasma 
HRG levels was performed by radial immunodiffusion 
(Mancini et al, 1965) as previously described (Boomsma 
et al, 1993). Using this method, HRG levels were determined 
in 126 healthy individuals. The mean HRG level was 99% 
(SD 20%) and the range 56-145%.
Electrophoretic mobility of HRG in the presence of Glu- 
plasminogen was studied by affinity crossed immuno- 
electrophoresis according to Kluft & Los (1988). Heparin 
binding was studied by affinity crossed immunoelectro- 
phoresis with 1 0 0 IU heparin per ml (Thromboliquine, 
Organon Teknika, The Netherlands) and 1 mM CuCl2 in the 
first dimension (Hoffmann et al, 1993).
Detection of polymorphisms. Genomic DNA was obtained 
from freshly collected blood as described previously 
(Wijmenga et al, 1990). Genotypes with respect to the 
dinucleotide repeat were detected by use of the polymerase 
chain reaction (PCR) with radiolabelled nucleotides (Hennis 
et al, 1992), using primers HRG-CA2F: 5' AAG CAG ACT 
TTG TCA TGG CAG TGC 3' and HRG-CA2R: 5' TTG CAC TCC 
TTT CCC CAG TTG TGG 31 (Isogen Bioscience, Amsterdam, 
The Netherlands). Individual genotypes were determined 
using a standard set of repeats of known length (Fig 2). The 
repeat is localized in the last intron of the HRG gene (Hennis 
etal, 1994).
Linkage. Linkage was carried out using the MIINK option of 
the LINKAGE computer program package, version 5.03 
(Lathrop & Lalomel, 1988). Linkage was calculated between 
the phenotype ‘HRG level’ and the dinucleotide repeat that is 
located in the last intron of the HRG gene. HRG levels were 
considered as a quantitative phenotype under the assumption 
that elevated HRG is a monogenic dominantly inherited trait 
(Ott, 1991). Two classes were distinguished: one with normal 
HRG levels (unaffected) and a second with high HRG levels 
(affected). In this approach the two classes were defined by a 
mean HRG level and a variance. For the class with normal 
HRG levels, a mean HRG of 99% and a variance of 400 was 
used in all calculations. This mean level and variance were 
derived from a control group of 126 volunteers. For the class 
with high HRG levels, lod scores were calculated for mean 
levels of 135%, 145%, 155% and 165%. The variance of HRG 
levels was assumed to be equal for both classes, The 
population frequency of high HRG levels was assumed to be 
0-05. No corrections for possible age effects on the HRG level 
have been implemented in the linkage analysis.
assays taking the intensity of oral anticoagulant treatment 
into account. Protein C, protein S activities and resistance to 
activated protein C were not determined in the proband who 
was on stable anticoagulant treatment. To exclude familial 
type II protein C or protein S deficiency or resistance to 
activated protein C, these parameters were measured in the 
spouse, several brothers and sisters and both the children of 
the proband. No abnormalities were found in the family 
members investigated. Fibrinolysis parameters were found to 
be normal in the proband. A minor elevation of u-PA activity 
was observed.
A persistently elevated level of HRG was found in the 
proband (161%, and 154% 3 years later). In nine other 
family members we also found high levels of HRG up to 
209% (see pedigree in Fig 1). The mean HRG level of all 
family members was 124%, which was high compared to the 
mean level found in 126 healthy individuals (99%, SD 20%:
Table I. Coagulation and fibrinolysis parameters in the proband’s
plasma.
Proband* Normal rangef
Clotting times
APTT (s) 29-4 28-0-39-2$
Prothrombin time (s) 17-0 17-0-19-0$
Thrombin clotting time (s) 16-1 14-3-18-5$
Coagulation factors
Fibrinogen (mg/ml) 2-2 1-8-4-9
Factor II antigen (%) 57 46-77$
Factor V activity (%) 100 52-124
Factor VII activity (%) 28 60-157
Factor VIII coagulant activity (%) 172 50-200
Factor X antigen (%) 61 31-76$
Von Willebrand factor antigen (%) 165 31-216
Antithrombin III activity (%) 91 75-120
Heparin cofactor II antigen (%) 115 61-185
Protein C antigen (%) 55 40-70$
Protein S antigen (%) 60 36-66$
Fibrinolysis factors
Plasminogen activity (%) 113 70-140
t-PA activity (mIU/ml) 13-2 >0
u-PA activity (ng/ml) 3-5 13-3*1
u-PA antigen (ng/ml) 4'3 1-7-6-2
Factor XII-dependent plasminogen
activator activity (%) 95 76-158
Plasminogen activator inhibition
activity (IU/ml) 6-4 1-7-34-0
a^-antiplasmin activity (%) 95 80—120
HRG antigen (%) 161/154§ 56-145
RESULTS 
Plasma levels
In order to exclude the possibility that the apparent familial 
thrombophilia was due to known or suspected disorders of 
fibrin formation and fibrinolysis, we studied the proband 
extensively on coagulation and fibrinolysis parameters 
(Table I). No abnormalities were found in the coagulation
* Oral anticoagulant treatment at the time of investigation with an 
intensity of 2-07 International Normalized Ratio.
t  Normal ranges were established in at least 42 healthy members 
of the laboratory staff. The normal range of HRG was established in 
126 healthy volunteers.
$ Values of 23 individuals on stable anticoagulant treatment with 
a mean of 2-4 International Normalized Ratio, which Is slightly 
higher compared to the intensity of anticoagulation in the proband.
§ A persistent elevated HRG antigen was confirmed after 3 years.
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Fig 2, Standard set of allele types of the 
dinucleoUde reptsut found 1» the* normal 
population. Genotypes (alleles 1 141 are 
noted at the bottom.
range 56-145%). Possible effects of assortative mating have 
been excluded in a previous parent-twin study on the 
heritability of HRG levels (Boomsma et al, 1993). Four 
women in generation III (III-ll, 111-15, III-17 and 111-18) 
used oral contraceptives which may lead to a decrease in 
HRG level of 20-25%  (Jespersen et al, 1990). One of these 
women (III-17) had an elevated HRG. The other three 
women had normal HRG, and this would not become 
elevated when a correction of 25% was applied. No 
corrections were therefore made for the usage of oral 
contraceptives.
A normal plasminogen and heparin binding of HRG was 
observed in an affinity crossed immunoelectrophoresis assay 
with plasma of the proband (data not shown).
Dinucleotide repeat genotypes
The with respect to dinucleotide repeat was
determined in all family members. Eight different allele 
types were found and heterozygosity was observed in 30/34  
family members (see pedigree in Fig 1). A standard set of 
allele types of the dinucleotide repeat is shown in Fig 2. Only 
in one marriage was information lost due to similar alleles of 
the dinucleotide repeat in father and mother (II-9 and 11-10). 
No evidence for recombinations or mutations was found 
within this pedigree.
Linkage
Linkage was performed regarding HRG levels as a quanti­
tative trait with a bimodal distribution caused by two classes. 
Lod scores and corresponding recombination fractions were 
calculated assuming a mean level of 99% for the class with 
normal HRG levels and different mean HRG levels (135%, 
145%, 155% and ,165%) for the class with high HRG levels.
Maximum lodscores for all analyses were found at 0  
indicating complete linkage. A maximum lod score of 4 ’
0
0  =  0, representing odds in favour for linkage of 46  0 0 0 :1 ,  
was found at the lowest mean level (13 5%) for the 
class. When the mean of the high-level class whs set at 
which was the highest HRG level of the normal range, a lod 
score of 4' 17 was found (odds in favour 
22 000:1). Higher mean values of 155% and 165% 
gave lod scores of 2*99 which represent odds in favour of 
linkage of 1000:1 .
In all calculations presented above, a population 
valence of elevated HRG levels of 5% was assumed. However 
lod scores did not show substantial chan lies
population prevalence was set at 10% or 1% (data not 
shown).
DinucleoUde repeal genotype and HRG k v d  
Elevated levels of HRG were frequently found In association 
with family members who carry allele 6 of the dinucleoUde 
repeat polymorphism, indicating that high HRG levels am 
linked to this allele. HRG levels of Individuals with 
were on average higher (149%, n »  1.3) than 
without allele 6 (109%, n = 25). The mean HRG level of ill
individuals was 124% (n 34).
The genotype was not In all cases predictive for an 
elevated HRG level (see pedigree in Fig 1). In five famllv
members a normal HRG level was found in c
t
with allele 6 (III-2, III-8, III-9, III-20,111-21). However, three 
out of these five Individuals did have a HRG level which Is 
above the mean HRG level In the family. An elevated HRG 
level was found in two individuals who did not 
a father (II-12) who was related by m an  
daughter (III-17).
curry
and his
850 B.C.  Hennis et al
HRG levels and thrombosis
Of the six family members with a history of thrombosis, three 
members had an elevated HRG level. One individual with a
allele 6 is coupled to elevated HRG (Hennis,
unpublished observations). Therefore it seems reasonable 
to assume that allele 6 itself is not related with raised HRG
history of thrombosis was related by marriage (II-15) and 
had no elevated HRG. Both grandparents had thrombosis 
but could not be included in the present analysis. Elevated 
HRG levels were also found in seven family members without 
a history of thrombosis.
levels and that the association between allele 6 and elevated 
HRG levels is most likely to be purely by linkage within this 
family.
Not all family members with allele 6 do have elevated HRG 
levels. It is possible that the lower levels of HRG in these 
family members are due to neutralizing effects caused by
DISCUSSION
In this paper we describe a family with familial thrombosis in
other HRG alleles, assuming that a multiallelic HRG locus is 
present. In one father (who is married into the pedigree) and 
his daughter, an elevated HRG level is found in the absence
which no known risk factors for thromboembolic disease 
could be found. The only abnormality observed was a high
of allele 6, suggesting that the HRG gene associated with 
elevation of HRG may also be coupled with other alleles of
level of HRG. By investigating this family, high levels of the dinucleotide repeat.
plasma HRG were found in 10/34 family members Linkage cannot discriminate between major and minor
distributed over two generations, suggesting a hereditary genes (i.e. the genetic background) that are involved in a
nature for this trait.
To investigate the possibility that specific HRG gene
given trait. It is therefore not possible to exclude a polygenic 
model. This may either be a model for a multi-allelic HRG
variants are associated with elevated plasma HRG levels in locus or a model involving different loci. In a recent parent
our family, we studied the inheritance pattern of a multi twin study (Boomsma et al, 1993) 69% of the variance in
allelic dinucleotide repeat which is located in the intron 
between the last two exons of the HRG gene (Hennis et al, 
1994). Due to the large number of alleles and a high degree 
of heterozygosity, little information is lost in the pedigree.
HRG level could be ascribed to genetic background. In such 
a study design the dinucleotide polymorphism could be used 
to determine the contribution of the HRG locus to the 
heritability.
Linkage was calculated between the dinucleotide repeat In theory, elevation of plasma HRG levels can be caused by
and plasma HRG levels regarding the HRG level as a an abnormality in the promoter region or elsewhere in the
quantitative trait and assuming a bimodal distribution of gene causing over-expression of the protein. An increased
HRG levels. Two classes, one with normal levels of HRG 
(unaffected) and a second with high levels of HRG (affected),
level can also be due to a deviating protein structure 
resulting in either increased synthesis or decreased clearance.
were defined by a mean and a variance. Using this approach, In the investigated family no indication was found for the
lod scores tended to decrease when the mean value for the 
class with high HRG levels was increased. This can be 
explained by a reduction of the overlap between the 
distributions of the two classes. The higher the mean HRG 
level of the high-level class was chosen, the more family
presence of an abnormal HRG molecule. Both the binding of 
heparin and plasminogen appeared to be normal in an 
affinity crossed immunoelectrophoresis assay. As yet, 
nothing has been reported about abnormal forms or 
polymorphisms of the HRG molecule in relation to either
members have a possibility to be assigned to the normal-level high HRG levels or thrombosis.
class. These individuals are then considered as recombinants 
which leads to lower lod scores.
By convention a lod score of 3 (odds in favour of linkage of
Another possibility is that the elevation of HRG is age 
dependent. In this family a statistically significant correla­
tion (r =  0-35, P < 0-05) was observed between age and
1000:1) is taken as a threshold for linkage. In the present 
family we found a maximum lod score of 4-65 and a 
minimum of 2-99, both at zero recombination, presenting 
substantial evidence for linkage. This may indicate a
HRG level. A comparable age-dependent increase with an 
even stronger correlation was found in a family described by 
Hoffmann et al (1993). Recently, it was also reported that 
parents have higher HRG levels than their children
significant effect of the HRG locus on plasma HRG levels in (Boomsma et al, 1993), but thus far no correlation between
general, although it may also be a unique effect in this 
family. In all calculations a population prevalence of
age and HRG level has been found in groups of unrelated 
healthy individuals (Hoffmann et al, 1993). Age may have
elevated HRG levels of 5% was assumed (Boomsma et al, consequences for linkage, because the overlap between the
1993). However, lod scores did not show substantial classes of normal and high HRG levels may be greater in
changes when the population prevalence was set at 10% the younger generation leading to more false recombinants.
or 1%.
The majority of the elevated HRG levels appeared to be
However, as the magnitude of the age effect is unknown, no 
corrections for age have been implemented in the linkage
coupled to allele 6 of the polymorphism (Fig 1). A marked analysis of this family.
difference was found between the average HRG level of In a previous report it is hypothesized that elevated HRG
family members with allele 6 and members without allele 6 
(149% v 109%). This result suggests a specific effect of the
levels may contribute to a prothrombotic state by reducing 
the availability of plasminogen which can be activated into
HRG gene which is coupled to allele 6, on the HRG level. The plasmin (Lijnen et al, 1980). Elevated HRG levels are found
allele frequency of allele 6 in a group of 130 healthy 
volunteers is 1*5%. In this group there is no indication that
in three out of six family members with thrombosis. 
However, due to the small number of family members with
Elevated HRG Levels associated with a Specific l7
a history of thromboembolic disease, no conclusions can be 
based on this particular family with respect to a causal 
relationship between thrombosis and elevation of HRG (see 
also pedigree in Fig 1). To study this relationship further, 
more families have to be included in future studies. In 
addition, characterization of the HRG gene and of the 
function of HRG in the haemostatic system are needed to 
understand the possible contribution of elevated HRG to the 
prothrombotic state. It is therefore important to screen the 
HRG gene for functional mutations or polymorphisms in 
families with high HRG levels,
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